| Therapeutic Area | Oncology - solid tumors |
|---|---|
| Indication | Advanced stage liver cancer |
| Objective | To complete pre-clinical validation of protein kinase X (PKX) as novel therapeutic agent in HCC |
| Type of Target | Novel HCC target |
| IP Status | Provisional application filed |
| Principal Investigator | Sylvain Meloche |
| Type of Partnership Sought | Research collaboration, license |
Competitive Advantages
• Access to a unique expertise in functional genomics and high throughput genome-scale RNAi loss-of-function screening
• Expertise in the primary culture of hepatocytes and human hepatocellular carcinoma (HCC) cells, and in the histopathological analysis of liver tumors
• Generation of novel proprietary validated targets for the treatment of HCC
• In-house capacity to move selective and potent lead inhibitors of HCC cells in in vivo proof-of-concept studies in a disease-relevant animal model to pharmacologically validate the selected therapeutic targets.
Kinase inhibitors (HCC) – Yes* (from june 2016 to may 2017_
Smal molecule inhibitors of ATPase activity (BRAHMA) from may 2017 to sept 2017
BMS_ Undisclosed target – Immunology – Biased signaling profiling of S1P ligands using BRET-based biosensor platform (from sept 2017 to